Clinical Trial Update: Comparison of Dual Antiplatelet Therapy De-escalation by Dose Reduction Versus Switching in Patients Undergoing PCI: The Switching Antiplatelet-8 (SWAP-8) Study [Phase 4]

View source ↗

Summary

Phase 4 SWAP-8 trial investigates de-escalating dual antiplatelet therapy after PCI by dose reduction versus switching in patients with coronary artery disease.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Coronary Artery Disease

Snippet

Sponsor: University of Florida | Conditions: Coronary Artery Disease | Phase 4 | Status: RECRUITING